Targeted therapies are diversifying treatment options in pancreatic ductal adenocarcinoma; however, numerous studies have also attempted to target other related signaling molecules, such as EGFR, MEK, and PI3K (Qian et al. 2020). Here, EGFR is linked to pancreatic ductal adenocarcinoma.